<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "erlotinib tab">
<dose><value>100</value>
<value>150</value>
<value>75</value>
</dose>
<route><value>PO</value>
</route>
<strength><value>100 mg</value>
<value>150 mg</value>
<value>25 mg</value>
</strength>
<frequency><value>DAILY</value>
</frequency>
<instruction></instruction>
<volume></volume>
<units><value>mg</value>
</units>
<Population><value>Erlotinib. Metastatic or Advanced NSCLC.</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>Dosage adjustments of 50mg due to drug interactions.</value>
<value>A reduced starting dose (75 mg po once daily) has been recommended in patients with (baseline) hepatic dysfunction (transaminases greater than or equal to 3 times ULN AND/OR total bilirubin greater than 3 times ULN).  For patients with normal baseline hepatic function: Treatment should be interrupted or discontinued if total bilirubin is greater than 3 time ULN AND/OR transaminases are greater than 5 times ULN occurs while on treatment.</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3387</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3385</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Formulary with Restrictions.</value>
</AHSFormularyStatus>
<AHFSName><value>Antineoplastic Agents</value>
</AHFSName>
<HighAlert><value>YES</value>
</HighAlert>
</drug>